Compare Stocks → The #1 Crypto That You Don’t Own… Yet (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison BATS:ARKGNYSEARCA:ARKKNASDAQ:EXAS Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARKGARK Genomic Revolution ETF$24.50-1.5%$25.68$0.00▼$0.00$1.38B1.99N/A2.79 million shsARKKARK Innovation ETF$42.45-0.8%$45.51$33.76▼$54.52$6.29B2.213.50 million shs12.83 million shsEXASExact Sciences$45.45+0.4%$60.61$43.59▼$100.77$8.35B1.263.79 million shs2.14 million shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARKGARK Genomic Revolution ETF-1.49%-4.41%+2.21%-22.54%-22.54%ARKKARK Innovation ETF-0.86%-4.35%-3.13%-16.99%+4.84%EXASExact Sciences+0.44%-8.81%-24.26%-23.54%-44.29%The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AN/AN/AEXASExact Sciences4.4559 of 5 stars3.54.00.04.72.72.50.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARKGARK Genomic Revolution ETF0.00N/A$45.4785.58% UpsideARKKARK Innovation ETF0.00N/A$59.8040.88% UpsideEXASExact Sciences2.92Moderate Buy$95.40109.90% UpsideCurrent Analyst RatingsLatest EXAS, ARKK, and ARKG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2024EXASExact SciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$90.00 ➝ $85.005/9/2024EXASExact SciencesBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$85.00 ➝ $80.005/9/2024EXASExact SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$100.00 ➝ $80.004/3/2024EXASExact SciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00(Data available from 6/1/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AEXASExact Sciences$2.50B3.36$0.02 per share2,656.97$16.98 per share2.68Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARKGARK Genomic Revolution ETFN/AN/A0.00∞N/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/A0.00∞N/AN/AN/AN/AN/AEXASExact Sciences-$204.15M-$1.32N/AN/AN/A-9.48%-7.12%-3.46%8/6/2024 (Estimated)Latest EXAS, ARKK, and ARKG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024Q1 2024EXASExact Sciences-$0.50-$0.50N/A-$0.40$624.95 million$637.52 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARKGARK Genomic Revolution ETFN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AEXASExact Sciences0.661.641.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences88.82%Insider OwnershipCompanyInsider OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences1.36%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARKGARK Genomic Revolution ETFN/A56.50 millionN/ANot OptionableARKKARK Innovation ETFN/A148.10 millionN/ANot OptionableEXASExact Sciences6,600184.53 million182.02 millionOptionableEXAS, ARKK, and ARKG HeadlinesRecent News About These CompaniesJune 1 at 6:53 AM | marketbeat.comTD Asset Management Inc Trims Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS)May 31 at 4:59 PM | marketbeat.comEvoke Wealth LLC Buys New Holdings in Exact Sciences Co. (NASDAQ:EXAS)May 31 at 2:18 AM | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Receives $95.40 Consensus PT from AnalystsMay 29 at 3:47 PM | marketbeat.comExact Sciences (NASDAQ:EXAS) Shares Down 5.3% May 29 at 12:30 PM | zacks.comExact Sciences (EXAS) Witnesses Rising Expenses, CompetitionMay 29 at 12:30 PM | zacks.comExact Sciences (EXAS) Witnesses Rising Expenses, CompetitionMay 29 at 5:23 AM | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Shares Purchased by Dimensional Fund Advisors LPMay 28, 2024 | marketbeat.comEdmond DE Rothschild Holding S.A. Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS)May 28, 2024 | marketbeat.comExact Sciences (NASDAQ:EXAS) Sets New 12-Month Low at $49.12May 28, 2024 | zacks.comExact Sciences (EXAS) to Showcase Favorable Research OutcomeMay 28, 2024 | businesswire.comExact Sciences to Participate in June Investor ConferencesMay 28, 2024 | marketbeat.comExact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of "Moderate Buy" from BrokeragesMay 27, 2024 | finance.yahoo.comHedge Funds are Bullish on This Cancer StockMay 27, 2024 | marketbeat.comArtisan Partners Limited Partnership Increases Stock Position in Exact Sciences Co. (NASDAQ:EXAS)May 27, 2024 | investorplace.comBull Market Blastoff: 3 Stocks Targeting 56% to 91% ReturnsMay 25, 2024 | marketbeat.comBI Asset Management Fondsmaeglerselskab A S Sells 36,605 Shares of Exact Sciences Co. (NASDAQ:EXAS)May 25, 2024 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Trading Down 5.6%May 24, 2024 | marketbeat.comExact Sciences (NASDAQ:EXAS) Shares Gap Down to $54.08May 24, 2024 | marketbeat.comNorges Bank Buys Shares of 1,626,228 Exact Sciences Co. (NASDAQ:EXAS)May 24, 2024 | businesswire.comExact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®May 23, 2024 | marketbeat.comExact Sciences (NASDAQ:EXAS) Shares Down 5.6% New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsARK Genomic Revolution ETFBATS:ARKGThe ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.ARK Innovation ETFNYSEARCA:ARKKThe ARK Innovation ETF (ARKK) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that seeks long-term capital growth from companies globally involved with, or that benefit from, disruptive innovation. ARKK was launched on Oct 31, 2014 and is managed by ARK.Exact SciencesNASDAQ:EXASExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
